BioNexus Gene Lab (BGLC) Non-Current Deferred Tax Liability (2018 - 2024)

BioNexus Gene Lab (BGLC) has 7 years of Non-Current Deferred Tax Liability data on file, last reported at $13646.0 in Q3 2024.

• For the quarter ending Q3 2024, Non-Current Deferred Tax Liability fell 52.75% year-over-year to $13646.0; the trailing twelve-month figure through Sep 2024 stood at $13646.0 (down 52.75% YoY), and the FY2023 full-year result was $12255.0, down 60.3% from the prior year.
• Non-Current Deferred Tax Liability advanced to $13646.0 in Q3 2024, from $11918.0 in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $30866.0 in Q4 2022 to a low of $1796.0 in Q3 2021.
• A 5-year average of $17840.3 and a median of $19593.5 in 2022 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability jumped 1452.12% in 2022 and tumbled 61.16% in 2024, its largest moves.
• Tracing BGLC's Non-Current Deferred Tax Liability over 5 years: stood at $1872.0 in 2020, then soared by 1417.95% to $28416.0 in 2021, then climbed by 8.62% to $30866.0 in 2022, then slumped by 60.3% to $12255.0 in 2023, then gained by 11.35% to $13646.0 in 2024.
• Business Quant data shows BGLC's Non-Current Deferred Tax Liability at $13646.0 in Q3 2024, $11918.0 in Q2 2024, and $11916.0 in Q1 2024.